On September 16, the U.S. Food and Drug Administration (FDA) approved Movantik (naloxegol), an oral treatment for opioid-induced constipation in adults with chronic non-cancer pain. Read more.
On September 16, the U.S. Food and Drug Administration (FDA) approved Movantik (naloxegol), an oral treatment for opioid-induced constipation in adults with chronic non-cancer pain. Read more.